Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Drug Development Efforts Are “Revolutionary,” Lilly’s Taurel Says

Executive Summary

FDA Commissioner McClellan's plan to accelerate drug development is "the single most encouraging story now emerging in our field," Lilly CEO Sidney Taurel declared during a Hudson Institute-sponsored luncheon in Washington, D.C. Nov. 4

You may also be interested in...



Rx Image Troubles Reflect Flaws In Health Insurance Coverage, Lilly CEO Says

A better health insurance system would help the image of the pharmaceutical industry, Lilly CEO Sidney Taurel declared during a Hudson Institute-sponsored luncheon in Washington, D.C. Nov. 4

IND Filings Hit Seven-Year Low In 2003; Where Is R&D Productivity Rebound?

Industry-sponsored IND submissions are running at their lowest level in seven years

Rx Image Troubles Reflect Flaws In Health Insurance Coverage, Lilly CEO Says

A better health insurance system would help the image of the pharmaceutical industry, Lilly CEO Sidney Taurel declared during a Hudson Institute-sponsored luncheon in Washington, D.C. Nov. 4

Related Content

UsernamePublicRestriction

Register

PS042780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel